Why is Moderna stock up today?

Traders Union
All News
Financial News
Moderna rises 4.06% today to $57.21

Highlights

Jefferies Financial Group reduced its Moderna stake by 25.3% during Q3, now holding shares worth $2.46 million.
Moderna expects up to 10% revenue growth in 2026, boosted by new partnerships, product launches, and pipeline advancements.
MRNA sustains a bullish technical structure with price action near highs; likely to consolidate in the $52.13–$53.90 range, with breakout potential above $60.00 resistance.

Stake reduction and cost cuts as new partnerships fuel outlook

Jefferies Financial Group reduced its stake in Moderna by 25.3% in the third quarter, selling 32,310 shares and holding 95,266 shares valued at $2.46 million according to recent SEC filings. Moderna reported $1.9 billion in revenue for 2025 and executed cost reductions exceeding $2 billion. The company highlighted expectations for up to 10% revenue growth in 2026 driven by new partnerships and product launches, with pipeline progress in oncology and norovirus, and settled patent litigation concerning its mRNA platform.

Anton Kharitonov, expert at Traders Union, sees recent price action as maintaining a bullish bias but warns of underlying risks. He notes the upward momentum above moving averages, yet flags institutional selling by Jefferies as a red flag for sentiment. Kharitonov remains cautious despite cost control efforts and new partnerships. He points to the key support at $48.11, stressing how a breakdown would shift the outlook quickly. "Investors should respect the technical trend but be prepared for volatility if current supports give way."

Viktoras Karapetjanc, expert at Traders Union, highlights the strong bullish structure and improving fundamentals. He sees Moderna’s forward guidance and product pipeline as backing further growth potential. Investor confidence remains robust despite a stake reduction by Jefferies, with momentum favoring higher levels. "The market offers attractive setups here — bullish structure remains intact and further gains are likely from current prices."

Multi-term bullish structure as price exceeds moving average cluster

MRNA’s current price of $57.21 is well above the MA-20 at $49.50, the MA-50 at $43.69, and the MA-200 at $31.42, confirming a strong short-, medium-, and long-term bullish structure. The nearest dynamic support is the Ichimoku Kijun at $48.11, while resistance is now defined by the psychological round level near $60.00.

Previously it was reported that Moderna Inc. remains in a bullish trend, trading well above key short-, medium-, and long-term moving averages, supported by strong momentum indicators such as MACD and ADX. However, several oscillators including RSI, CCI, and Stoch RSI are signaling overbought conditions, suggesting a risk of near-term exhaustion or pullback despite continued upward momentum, with immediate dynamic support at the MA-50 and Ichimoku Kijun levels.

Source of Data: MRNA Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.